Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty pharmaceutical company, is pleased to announce the…


Previous articleMindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Next articlePsyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note